Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07272655

AAR/AAR+HAR vs AAR+TAR+FET for Type A Aortic Intramural Hematoma

This is a prospective, randomized, non-inferiority clinical trial designed to compare the efficacy and safety of two surgical strategies for acute type A aortic intramural hematoma (TAIMH): (1) ascending aorta replacement or ascending aorta plus hemiarch replacement (AAR/AAR+HAR), and (2) ascending aorta replacement with total arch replacement and frozen elephant trunk implantation (AAR+TAR+FET). Patients will be enrolled based on CTA confirmation of a completely thrombosed false lumen in the ascending aorta and aortic arch. Eligible participants will be randomized in a 1:1 ratio to either group. The primary endpoint is the rate of reintervention on the aortic arch or descending aorta from 6 to 12 months after surgery. Secondary endpoints include circulatory arrest time, aortic cross-clamp time, major adverse cardiovascular events, other perioperative complications, and total hospitalization cost. A total of 400 participants will be enrolled.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

This is a prospective, randomized, controlled, non-inferiority study comparing two surgical strategies for acute type A aortic intramural hematoma (TAIMH). Patients with acute TAIMH will be screened and enrolled based on CTA confirmation of a completely thrombosed false lumen in the ascending aorta and aortic arch. Participants will be randomly assigned in a 1:1 ratio to receive either AAR/AAR+HAR or AAR+TAR+FET, with 200 participants in each group. Postoperative CTA will be performed before discharge, and follow-up CTA will be performed at 6 to 12 months after surgery.

The surgical procedure will be performed through a median sternotomy or upper partial sternotomy. Cardiopulmonary bypass will be established through right axillary/femoral arterial and bicaval venous cannulation, or femoral arteriovenous cannulation and superior vena cava cannulation. Left ventricular venting will be achieved via the right superior pulmonary vein. Antegrade HTK or cold blood cardioplegia will be administered under direct vision and repeated every 30 minutes. During circulatory arrest, bilateral selective antegrade cerebral perfusion will be provided via the right axillary artery and left common carotid artery.

The primary endpoint is the rate of reintervention on the aortic arch or descending aorta from 6 to 12 months after surgery. Secondary endpoints include circulatory arrest time, aortic cross-clamp time, major adverse cardiovascular events, other perioperative complications, and total hospitalization cost. The trial is designed to test whether the less extensive AAR/AAR+HAR strategy is non-inferior to AAR+TAR+FET with respect to the primary endpoint, while potentially offering advantages in operative burden, perioperative safety, and hospitalization cost.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years and ≤ 80 years.
  • Diagnosis of type A aortic intramural hematoma (TAIMH).
  • Ability to understand the study procedure and provide written informed consent.

Exclusion criteria

  • Preoperative CTA shows an open or partially thrombosed (mixed) false lumen in the ascending aorta or arch.
  • Primary tear located on the greater curvature of the aortic arch, necessitating total arch replacement.
  • Planned concomitant major cardiac surgery (e.g., CABG, valve replacement, atrial fibrillation ablation).
  • Previous history of aortic arch or distal aortic surgery.
  • Severe peripheral vascular disease or cerebrovascular anatomy abnormality.
  • Active systemic infection, malignancy, severe hepatic or renal dysfunction, or other major comorbidities with life expectancy < 1 year or deemed unfit for complex cardiovascular surgery.
  • Pregnancy or lactation.
  • Severe psychiatric or cognitive disorders affecting compliance or follow-up.

Treatment and study plan

Ascending Aorta Replacement / Ascending Aorta Plus Hemiarch Replacement

Procedure

This procedure involves ascending aorta replacement alone or ascending aorta plus hemiarch replacement, according to the operative strategy. The ascending aorta is replaced with or without replacement of the proximal aortic arch, while the distal arch and supra-aortic vessels are preserved.

Other names: AAR/AAR+HAR

Ascending Aorta Replacement With Total Arch Replacement and Frozen Elephant Trunk

Procedure

This procedure involves ascending aorta replacement with total arch replacement and frozen elephant trunk implantation. The entire aortic arch is replaced, and a frozen elephant trunk is implanted into the proximal descending aorta.

Other names: AAR+TAR+FET

Primary outcomes

  1. Rate of reintervention on the aortic arch or descending aorta

    Time frame: 6 to 12 months after surgery

    The proportion of patients requiring any secondary surgical or endovascular procedure involving the aortic arch or descending aorta during follow-up after the index operation.

Secondary outcomes

  1. Aortic Cross-Clamp Time

    Time frame: Intraoperative

    Duration (minutes) of aortic cross-clamping during surgery.

  2. Circulatory Arrest Time

    Time frame: Intraoperative

    Duration (minutes) of total circulatory arrest.

  3. Major Adverse Cardiovascular Events (MACE)

    Time frame: Through 30 days after surgery

    Incidence of major adverse cardiovascular events during the perioperative period. The exact components should follow the study protocol and statistical analysis plan.

  4. Other perioperative complications

    Time frame: Through 30 days after surgery

    Incidence of perioperative complications during the perioperative period, including but not limited to neurological events, renal dysfunction, infection, bleeding, and cardiac failure.

  5. Total hospitalization cost

    Time frame: Through hospital discharge

    The total direct medical cost incurred during the index hospitalization, including surgery, intensive care, ward stay, medications, blood products, imaging, laboratory tests, procedures, and other treatment-related in-hospital expenses.

Study contacts

Contact information is provided by the study sponsor or research team.

kexiang liu, MD,Ph.D.

CONTACT

[email protected]

17390920328

Sponsors and collaborators

Lead sponsor

Second Hospital of Jilin University

Other

Registry information

Official study title

A Prospective, Randomized, Non-Inferiority Trial of AAR/AAR+HAR Versus AAR+TAR+FET in Type A Aortic Intramural Hematoma

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Dec 9, 2025
Registry last updated
May 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.